Scrip Asks… What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking
January 9, 2026
"Marc Salzberg, CEO and chief medical officer of Airway Therapeutics, positioned it even more boldly: “Looking into 2026, capital allocation and dealmaking will concentrate on rare diseases, reflecting a strategic shift across pharmaceutical companies and investors. Competitive high-incidence indications focusing on common targets will be gradually replaced by less crowded rare diseases. Advances in study designs, genomics and regulatory incentives reduce development risks while improving the probability of clinical and commercial success. Rapid market penetration coupled with attractive pricing represent additional incentives. M&A activity, partnerships and venture funding are expected to disproportionately favor orphan indications.”"... full article
Daniele De Luca, MD, discusses zelpultide alfa in neonates at high risk of bronchopulmonary dysplasia development
November 21, 2025
A phase 1b study of zelpultide alfa demonstrated a favorable safety profile and encouraging early reductions in BPD and ventilation duration, supporting advancement to a pivotal international Phase 2b/3 program.... full article
BioSpace with Tristan Manalac, 5 Biotechs Taking the Pipeline-in-a-Product Approach to Drug Development
August 20, 2025
The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can be a goldmine for smaller companies... full article
Informa’s BioXconomy with Millie Hoe
August 15, 2025
The company will trial its compound zelpultide alfa in over 300 pre-term neonates with bronchopulmonary dysplasia... full article
Pharma Focus Europe Editorial Team
August 13, 2025
Airway Therapeutics, Inc., a clinical-stage biopharmaceutical company developing biologic therapies for respiratory, inflammatory, and infectious diseases, has received approval from the European Medicines Agency’s (EMA) Paediatric Committee (PDCO) for its Paediatric Investigation Plan (PIP) for zelpultide alfa... full article
MedPath Editorial Team
August 12, 2025
Airway Therapeutics announced that the European Medicines Agency (EMA) Pediatric Committee (PDCO) has approved its Pediatric Investigation Plan (PIP) for zelpultide alfa... full article